ArticleBMC cancer2025
The combination of anti-PD-1 antibodies, trastuzumab and chemotherapy may improve the outcome of some patients with HER2-positive alpha-fetoprotein-producing gastric cancer: a retrospective real-world analysis from a single center.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundPatients with alpha-fetoprotein-producing gastric cancer (AFPGC) characterized with elevated serum AFP levels have received increased interest because of their aggressive behavior and poor prognosis. AFPGC patients who are HER2 positive are even poorer.
methodsA single-center retrospective real-world analysis was conducted in patients with histologically confirmed gastric cancer, an AFP level > 7 ng/ml and who were pathologically HER2 positive at Tianjin Medical University Cancer Institute. Clinical characteristics, treatments and survival were recorded. The last follow-up date was February 10, 2023. The immune microenvironment was detected via multiple immunofluorescence stains.
resultsFrom May 2017 to May 2022, 29 advanced patients who were HER2 positive were included in the final analysis of 259 AFPGC patients. The median AFP level was 6745.13 ng/ml. Sixteen patients (61.5%) received the quadruplet combination of doublet chemotherapy, trastuzumab and anti-PD-1 antibody. The ORR and DCR were 66.7% and 91.7% in all patients, and 80% and 93.3% in patients in the quadruple combination group. The median progression-free survival (mPFS) and overall survival (mOS) for all patients were 10.27 and 20.50 months, respectively. For the quadruplet combination group, the mPFS and mOS were 7.47 and 14.87 months, respectively, but there were still 6 patients without disease progression and 8 patients who were alive (PFS and OS range: 7.3-41.07 months). Multiple immunofluorescence stains revealed significantly fewer CD3 + , CD8 + , CD56 + , and CD68 + immune cells in the tumor parenchyma and stroma in HER2-positive AFPGC patients than in HER2-negative and AFP-normal gastric cancer patients.
conclusionsCompared with current treatments, parts of HER2-positive AFPGC can achieve equivalent ORR and survival benefits, especially with HER2-targeted, anti-PD-1 antibody and chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.